Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Published:2020-03 Issue:3 Volume:21 Page:387-397
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Garassino Marina C,Gadgeel Shirish,Esteban Emilio,Felip Enriqueta,Speranza Giovanna,Domine Manuel,Hochmair Maximilian J,Powell Steven,Cheng Susanna Yee-Shan,Bischoff Helge G,Peled Nir,Reck Martin,Hui Rina,Garon Edward B,Boyer Michael,Wei Ziwen,Burke Thomas,Pietanza M Catherine,Rodríguez-Abreu Delvys

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study;Iyer;Support Care Cancer,2014

2. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany;Iyer;Lung Cancer,2013

3. Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer;Reck;N Engl J Med,2016

5. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer;Translational Research;2024-10

2. Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC;Scientific Reports;2024-09-13

3. Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer;Journal of Inflammation Research;2024-09

4. Immune‐inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer receiving first‐line immunotherapy;Thoracic Cancer;2024-08-27

5. Real-World Comparison of Health-Related Quality of Life Associated with Use of Immune-Checkpoint Inhibitors in Oncology Patients;Journal of Clinical Medicine;2024-08-20